Navigation Links
Use of naltrexone reduces inflammation in Crohn's patients
Date:5/19/2011

Naltrexone reduced inflammation in Crohn's patients in a research study at Penn State College of Medicine.

Crohn's disease is a chronic inflammatory condition of the gastrointestinal tract causing abdominal pain, diarrhea, gastrointestinal bleeding and weight loss. Treatments for Crohn's disease are designed to reduce the inflammation but may be associated with rare but serious side effects, including infections and lymphoma. Research suggests that endorphins and enkephalins, part of the opioid system, have a role in the development or continuation of inflammation.

Naltrexone is a drug used to help recovering alcoholics and drug users stay clean. It inhibits the body's opioid system that regulates pain and is involved in cell growth, repair and inflammation. Naltrexone binds to a protein receptor that blocks the effects of opioids, including the body's own enkephalins and endorphins, substances that reduce pain and produce a feeling of wellbeing.

"Although the cause of Crohn's disease is unknown, research suggests it involves a complex interplay of environmental, genetic, microbial, immune and nonimmune factors," said Jill P. Smith, M.D., professor of medicine. "We hypothesize that the opioid system is involved in inflammatory bowel disease and that interfering with an opioid receptor will lead to the reversal of the inflammation."

Researchers studied 40 patients with active Crohn's disease. Patients received either naltrexone or a placebo for 12 weeks. All patients then continued on naltrexone for an additional 12 weeks. This was a double-blind study with neither the patient or healthcare provider knowing which treatment was being received.

Eighty-eight percent of those treated with naltrexone had at least a 70-point decline in Crohn's Disease Activity Index scores compared to 40 percent of placebo-treated patients. CDAI is a point system used to quantify symptoms in Crohn's patients. Researchers noted no statistical difference at four or eight weeks of treatment, suggesting a response requires at least 12 weeks of treatment. Results were published in the journal Digestive Diseases and Sciences.

Gastrointestinal inflammation was evaluated by appearance of the intestine on colonoscopy and scores from biopsy specimens. After 12 weeks, researchers noted no change in those taking a placebo. However, 78 percent of those on naltrexone experienced healing in the lining of the intestine.

For those patients who received a placebo for 12 weeks and then were placed on naltrexone for the following 12 weeks, 70 percent experienced at least a 70-point decline in the CDAI score and healing of the colon as seen on colonoscopy. Patients who continued use of naltrexone for an additional 12 weeks (24 total weeks) had a further 75-point decline in CDAI scores, leading to remission (score of less than 150) in 50 percent of the patients.

"We report that naltrexone improves clinical and inflammatory activity of subjects with moderate to severe Crohn's disease compared to placebo-treated controls," Smith said.

The researchers are planning clinical trials to look at use of naltrexone in children with Crohn's disease and have secured orphan drug status from the Food and Drug Administration for the use of naltrexone in children with Crohn's disease. Smith and Zagon hold a patent for the use of naltrexone in inflammatory bowel disease -- Crohn's disease and ulcerative colitis.


'/>"/>

Contact: Matthew Solovey
msolovey@hmc.psu.edu
717-531-8606
Penn State
Source:Eurekalert

Related medicine news :

1. Service Foods Reduces its Carbon Footprint and Grows Sales
2. Health Care Reform Report Covers Uninsured, Reduces Costs
3. New cardiac CT technology drastically reduces patient radiation exposure
4. Accelerated radiation therapy reduces toxicity in patients with advanced head and neck cancers
5. Targeted delivery of losartan reduces liver inflammation and scarring
6. Drug dramatically reduces nausea and vomiting in bone marrow transplant patients
7. Soccer reduces risk of falls and bone fractures
8. Pioneering treatment reduces disability in premature babies with serious brain hemorrhage
9. New drug candidate reduces blood lipids
10. PSA Test Reduces Prostate Cancer Deaths by 40%
11. New technique reduces tobacco smoke damage to lungs in mice
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/5/2016)... ... 05, 2016 , ... Chronic stress can have a silent, yet dangerous, impact ... immune system and increase inflammation, both of which raise the risk of heart attack ... disease program at Harvard-affiliated Massachusetts General Hospital. Chronic stress also can lead to other ...
(Date:5/5/2016)... , ... May 05, 2016 , ... ... honored finalists and winners Tuesday evening, May 3, at the 2016 ISE® Central ... , Scott Pettigrew, Vice President and Chief Security Officer of HMS, was selected ...
(Date:5/5/2016)... , ... May 05, 2016 , ... If you don’t ... marks on your skin, you may want to consider a treatment that some have ... Advanced Dermatology P.C. , Microneedling, also known as skin needling, is a ...
(Date:5/5/2016)... Austin, TX (PRWEB) , ... May 05, 2016 , ... ... existence to offer the breakthrough technology of the new PiQo4™ laser, the first 4-wavelenth ... treating more tattoo inks than any other picosecond laser on the market. Jeremy ...
(Date:5/5/2016)... ... 05, 2016 , ... Liposuction specialist Marcia V. Byrd, MD spoke last month ... the Marriot St. Louis Airport Hotel. This year’s conference was titled “Living with Lipedema ... her unique specialization in treating Lipedema. Dr. Byrd is considered one of the leading ...
Breaking Medicine News(10 mins):
(Date:5/3/2016)... CITY, Mo. , May 3, 2016 /PRNewswire/ ... Kansas Medical Center,s Institute for Advancing Medical Innovation ... and commercialize new drugs, diagnostics and medical devices. ... provides BioNovus Innovations with rights to license, develop ... "This partnership represents ...
(Date:5/3/2016)... , May 3, 2016  As a teenager, an ... rheumatic fever, which damaged his heart. He continued enjoying ... by June 2013, Shepherd,s heart was giving out and ... On June 20, 2013, the Mesa, Arizona ... Heart (TAH-t). Like a heart transplant, the SynCardia TAH-t ...
(Date:5/3/2016)...  While you may be familiar with watching a film or TV show in high definition, ... 8MP in the Medical Industry.  Ampronix  is a renowned authorized reseller of the medical industry,s ... - http://photos.prnewswire.com/prnh/20160502/362730 ... ... ...
Breaking Medicine Technology: